Research programme: lamellarins - PharmaMarAlternative Names: Lamellarin D
Latest Information Update: 14 Apr 2009
At a glance
- Originator PharmaMar
- Class Alkaloids
- Mechanism of Action DNA topoisomerase I inhibitors; P-glycoprotein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 14 Apr 2009 Discontinued - Preclinical for Cancer in Spain (unspecified route)
- 05 Dec 2007 This programme is still in active development
- 05 Aug 2005 This programme is still in active development - (BIO-2005)